Full article: https://www.ajronline.org/doi/10.2214/AJR.22.28233 

Across practices, Eovist is used to differentiate focal nodular hyperplasia (FNH) from hepatic adenoma (HCA). Mohanned Alnammi, MD discusses how further research and new updates in HCA classification system, combined with new data from a recent AJR article shows how Eovist uptake occurs in these subtypes (namely B-HCA which has malignant potential).